Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI)
- Createtime： 2026-04-14
- Updatetime： 2026-04-15
Product Details
| useage |
Industrial use
|
| deliveryInfo |
|
| appearance |
powder
|
| Storage Condition |
Long-term at -20 °C, short-term at +4 °C; keep cool, dry, sealed, away from heat and oxidants
|
| aliasen |
|
| supplyCapacity |
50000Metric Ton/Month
|
| Solubility |
Soluble in DMSO (30 mg/mL), DMF (25 mg/mL); slightly soluble in water
|
| harbor |
Qingdao,China
|
| minorder |
1KG
|
- Assay (HPLC): ≥98.0% (typically ≥99.0%)
- Melting Point: 151–155 °C (dec.)
- Loss on Drying: ≤0.5%
- Single Impurity: ≤0.3%
- Total Impurities: ≤1.0%
- Heavy Metals: ≤10 ppm
- Residue on Ignition: ≤0.1%
Applications
Favipiravir (T-705) is a broad-spectrum antiviral API targeting RNA-dependent RNA polymerase (RdRp), blocking viral RNA replication. Active against influenza A/B, avian flu, Ebola, RSV, and coronaviruses. Used as oral antiviral drug for influenza and emerging viral infections; also in research for other RNA virus diseases.
Safety Information
GHS Classification: Self-reactive substance (Type C, H242: Heating may cause fire); Germ cell mutagenicity (Category 2, H341: Suspected of causing genetic defects); Reproductive toxicity (Category 2, H361d: Suspected of damaging fertility or the unborn child).
- Inhalation: Dust may irritate respiratory tract; avoid inhalation.
- Skin: May cause irritation; wear chemical-resistant gloves.
- Eye: May cause irritation; wear safety goggles.
- Ingestion: May cause gastrointestinal discomfort; do not ingest.
- Storage: Keep away from heat, ignition sources, and incompatible materials.
- Disposal: Treat as hazardous waste per local regulations.
